A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
A Phase I, Single-arm, Open Label, Dose Escalation, Multicenter Study of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
Sponsor: Sanofi
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Sanofi
Other Acute Myeloid Leukaemia trials with similar outcome
Listed as NCT05712278, this PHASE1 trial focuses on Acute Myeloid Leukaemia and remains terminated or withdrawn. Sponsored by Sanofi, it has been updated 13 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
May 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
▶ Show 8 earlier versions
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2024 — Mar 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE1
-
Aug 2023 — Dec 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE1
-
Apr 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE1
-
Mar 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .